Beta-Caryophyllene; The Cannabinoid You May Have Been Waiting For
It’s no secret that Big Pharma likes things to come neatly in pill form, and marijuana is no exception. The alternative world has embraced whole foods diets and whole foods medicine. Marijuana, totally unprocessed, has the power to heal us from so many troubles; physical, psychological and emotional. But what about those in need of a weed that won’t get them high? For example, truck drivers who suffer from arthritis, or school teachers with muscular dystrophy.
Until recently, only synthetic products were available to ease their pain. Drugs like Marinol are produced in a laboratory and distributed at high cost. There are so many reasons why this is disappointing. First of all, weed is a plant, that is one of the factors that makes weed so dear to us. You can heal yourself with a seed, soil, sunlight and a little water. Taking that freedom away from us and handing it over to the large medical industry is a loss of freedom. But what can we do? Only they have the technology to create the medicine.
Two recent events have liberated high-free weed for the people. One is an Israeli strain of bud which can be grown just like any other bud. The “rafael” strain of weed is low THC high CBD. One could theoretically obtain seeds and grow.
The second event is the discovery of an entirely new cannabinoid – Beta-Caryophyllene (BCP). BCP is not unique to Cannabis sativa, it can be found in the essential oils of many grocery store plants like rosemary, black pepper and cloves. It is also present, of course, in marijuana and hops.
BCP has been around for a long time. It was first synthesized in the 1960’s. Seven years ago BCP was found to be a cannabinoid by Swiss and German researchers. This led to the discovery that BCP works specifically on CB2 cannabinoid pathways, the pathways that don’t get you high. CB1 receptor pathways, those which, when activated cause psycho-active effects, are not at all effected by BCP.
CB2 selective cannabinoids have been the goal of scientists for a long time now. Many do now exist and are used for patients with inflammatory diseases such as bladder cystitis, HIV- associated dementia, arthritis and multiple sclerosis.
In many cases the naturally occurring version of a compound is significantly more effective than its synthetic counterparts. Mostly likely Beta-Caryophyllene is no exception. Whether or not this fact is recognized by the pharmaceutical industry, hard science backs it up. So the next time you need to treat yourself with CB2 selective cannabinoids, you can head straight to your local grocer.